“Johnson & Johnson’s single dose vaccine has shown substantial protection for use in the general population “ announces the US company presenting the data of a new study on real data with respect to an infected, hospitalized and vaccinated population in the USA.
This study, according to Johnson & Johnson, demonstrates stable vaccine efficacy of 79% (CI, 77% -80%) for COVID-19-related infections and 81% (CI, 79% -84%) for hospitalizations. related to COVID-19. There was no evidence of reduced efficacy over the duration of the study, including when the Delta variant became dominant in the United States. The study included 390,000 people who received Johnson & Johnson’s COVID-19 vaccine and approximately 1.52 million unvaccinated people compared for age, sex, date, zip code, and comorbidities and predictors for severity of the disease. COVID-19 infection conducted from March to late July 2021.
A second dose at two months provided 94% (CI, 58% -100) protection against COVID-19 in the United States.
The Phase 3 ENSEMBLE 2 study demonstrated that a second dose of Johnson & Johnson’s COVID-19 vaccine given 56 days after the first provided:
- 100% protection (CI, 33% -100%) against severe / critical forms of COVID-19 – at least 14 days after final vaccination.
- 76% protection against symptomatic forms of COVID-19 globally (CI, 55% -88%).
- 94% protection against symptomatic forms of COVID-19 in the United States (CI, 58% -100%).
The six-month booster provided a 12-fold increase in antibodies
When a Johnson & Johnson COVID-19 vaccine booster was given six months after the single injection, the antibody levels increased nine-fold a week after the booster and continued to rise up to 12-fold. four weeks after the recall.